Conversely, a phase I study (NCT02773459) exploring binimetinib (MEK1/2 inhibitor) and capecitabine in patients with advanced or metastatic CCA with RAS/RAF/MEK/ERK pathway alterations showed encouraging anti-tumor effects. This evidence concerns the gene MAP2K1 and neoplasm.